Abstract
Background
Serum cardiac troponin I (cTnI) is a sensitive and specific marker of myocardial injury. However, a systematic evaluation of cTnI in hypertrophic cardiomyopathy (HCM) patients has not been performed.
Hypothesis
The purpose of this study is to evaluate cTnI and determine its relationship to clinical features in HCM.
Methods
We studied serum cTnI in 162 consecutive HCM patients.
Results
Serum cTnI ranged from 0.01 to 0.83 ng/mL (mean, 0.068 ± 0.100 ng/mL) and was higher in male patients (P < .001), those with atrial fibrillation (P = .033), and left ventricular (LV) systolic dysfunction (P = .046). Serum cTnI values were also correlated with maximum LV wall thickness (r = 0.30, P < .001), LV end‐systolic diameter (r = 0.20, P = .012), and E/Ea (peak early transmitral filling velocity/early diastolic mitral annulus velocity; r = 0.24, P = .004). Serum cTnI levels were not significantly different among New York Heart Association (NYHA) functional class and there was no difference between patients with or without LV outflow tract obstruction; although B‐type natriuretic peptide (BNP) levels showed significant difference in those variables. Serum cTnI had very weak correlation with BNP values (r = 0.18, P = .023). Multivariate analysis revealed an independent relationship between cTnI and maximum LV wall thickness, E/Ea, and male gender.
Conclusions
In patients with HCM, serum cTnI was associated with important clinical indices such as maximum LV wall thickness, LV dysfunction, and male gender. Serum cTnI seemed to have clinical significance different from that of BNP and may not be reflecting cardiac load but the LV remodeling process in HCM. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (362.5 KB).
References
- 1. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369–374. [DOI] [PubMed] [Google Scholar]
- 2. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833–838. [DOI] [PubMed] [Google Scholar]
- 3. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775–785. [DOI] [PubMed] [Google Scholar]
- 4. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308–1320. [DOI] [PubMed] [Google Scholar]
- 5. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778–1785. [DOI] [PubMed] [Google Scholar]
- 6. Biagini E, Coccolo F, Ferlito M, et al. Dilated‐hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005; 46: 1543–1550. [DOI] [PubMed] [Google Scholar]
- 7. Petersen SE, Jerosch‐Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy; new insights from multiparametric magnetic resonance imaging. Circulation 2007; 115: 2418–2425. [DOI] [PubMed] [Google Scholar]
- 8. Thaman R, Esteban MT, Barnes S, et al. Usefulness of N‐terminal pro‐B‐type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 2006; 98: 515–519. [DOI] [PubMed] [Google Scholar]
- 9. Maron BJ. Tholakanahalli VN, Zenovich AG, et al. Usefulness of B‐type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 2004; 109: 984–989. [DOI] [PubMed] [Google Scholar]
- 10. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000; 84: 476–482. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end‐stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114: 216–225. [DOI] [PubMed] [Google Scholar]
- 12. Nakamura T, Sakamoto K, Yamano T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non‐obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41: 315–321. [DOI] [PubMed] [Google Scholar]
- 13. Takeuchi I, Inomata T, Nishii M, et al. Clinical characteristics of heart disease patients with a good prognosis in spite of markedly increased plasma levels of type‐B natriuretic peptide (BNP); anomalous behavior of plasma BNP in hypertrophic cardiomyopathy. Circ J 2005; 69: 277–282. [DOI] [PubMed] [Google Scholar]
- 14. Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, Basaran Y. Usefulness of N‐terminal pro‐B‐type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 2006; 98: 1504–1506. [DOI] [PubMed] [Google Scholar]
- 15. Pieroni M, Bellocci F, Sanna T, et al. Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Cardiac Fail 2007; 13: 380–388. [DOI] [PubMed] [Google Scholar]
- 16. Perna ER, Macin SM, Cimbaro JP, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high‐risk patient identification. Circulation 2004; 110: 2376–2382. [DOI] [PubMed] [Google Scholar]